Experts, investors and prestigious grants accelerate revolution in cancer diagnostics

Slovak biotechnology company Glycanostics is making remarkable progress in developing revolutionary non-invasive tests for early cancer detection. With investment and support from Crowdberry investors, the company has expanded its team with top experts, secured prestigious grants, and moved closer to obtaining CE certification, which will enable entry into international markets.

What other key milestones has the company achieved and what lies ahead? We've summarized the key insights that highlight why investing in Glycanostics makes financial sense. The investment opportunity closes on February 8, so this is a last chance for investors to become involved.

Prestigious grants drive development of new tests

Glycanostics' innovative solutions, based on patented glycan analysis technology, have received backing from major research and development grant programs.

A grant from the recovery and resilience Plan under the EIC Transition scheme is accelerating the development of non-invasive tests for breast, pancreatic and lung cancer, advancing them into clinical validation.